SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present preclinical data on the company’s novel DYRK1A inhibitor, SM07883, a potential first-in-class drug for the treatment of Alzheimer’s disease, as a poster presentation at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, to be held in Barcelona, Spain, October 24-27, 2018.
“Based on the association between DYRK1A expression and Alzheimer’s pathology, we believe SM07883 has significant potential as a treatment for Alzheimer’s disease. We look forward to sharing our findings at CTAD 2018,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed.
Samumed’s poster entitled, “SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease” will be available for viewing during the conference. Further details can be found on the CTAD website at http://www.ctad-alzheimer.com/. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website following the conclusion of the conference.
About the 11th Clinical Trials in Alzheimer’s Disease (CTAD) Congress
CTAD brings together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. CTAD 2018 will highlight the latest on trying to get these trials off the ground. Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.
About Alzheimer’s Disease
Alzheimer’s disease (AD), the most common cause of dementia, is a chronic neurodegenerative disease affecting an estimated 5.5 million people in the US and over 46 million people worldwide. The disease is initially characterized by progressive memory loss and then slow progression to severe difficulty in accessing basic brain functions, prompting mental disorders. With the world’s aging population, AD is quickly becoming “The Disease of the Century,” a global epidemic and a socio-economic burden impacting families, social service, and healthcare delivery systems. Currently available therapies treat symptoms, not the disease itself, which is ultimately fatal.
About Samumed and SM07883
SM07883 is an oral small molecule dual-specificity tyrosine phosphorylation-regulated kinase-1A (DYRK1A) inhibitor being developed as a potential therapy for the treatment of Alzheimer’s disease. Preclinical data suggested that, compared to controls, SM07883 reduced Tau hyperphosphorylation/overexpression and neuroinflammation. Additional information on Samumed’s SM07883 Alzheimer’s disease program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=18
Learn more about Samumed’s technology platform and potential regenerative drug candidates at https://www.samumed.com/pipeline/default.aspx
Corporate Contact:
Erich Horsley
Samumed, LLC
erich@samumed.com
858-365-0200
Investor Contact:
Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-535-7742
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt@lifescipublicrelations.com
646-627-8384